Bicycle Therapeutics (BCYC) Competitors $7.85 +0.17 (+2.23%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, HRMY, ADPT, and SRPTShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors CG Oncology Kiniksa Pharmaceuticals International Beam Therapeutics IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Adaptive Biotechnologies Sarepta Therapeutics Bicycle Therapeutics (NASDAQ:BCYC) and CG Oncology (NASDAQ:CGON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Is BCYC or CGON more profitable? Bicycle Therapeutics has a net margin of -790.07% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -16.71% beat Bicycle Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-790.07% -25.54% -21.23% CG Oncology -15,945.17%-16.71%-16.24% Does the media favor BCYC or CGON? In the previous week, CG Oncology had 6 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for CG Oncology and 1 mentions for Bicycle Therapeutics. CG Oncology's average media sentiment score of 1.57 beat Bicycle Therapeutics' score of 0.79 indicating that CG Oncology is being referred to more favorably in the news media. Company Overall Sentiment Bicycle Therapeutics Positive CG Oncology Very Positive Which has more volatility & risk, BCYC or CGON? Bicycle Therapeutics has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Which has stronger earnings & valuation, BCYC or CGON? CG Oncology has lower revenue, but higher earnings than Bicycle Therapeutics. CG Oncology is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$25.72M21.14-$169.03M-$3.14-2.50CG Oncology$1.14M1,710.14-$88.04M-$1.51-16.94 Do institutionals and insiders have more ownership in BCYC or CGON? 86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer BCYC or CGON? Bicycle Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 218.43%. CG Oncology has a consensus target price of $55.30, suggesting a potential upside of 116.20%. Given Bicycle Therapeutics' higher possible upside, research analysts clearly believe Bicycle Therapeutics is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70CG Oncology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08 SummaryCG Oncology beats Bicycle Therapeutics on 10 of the 17 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$545.65M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-2.5120.3528.6119.64Price / Sales21.14304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book0.687.718.185.63Net Income-$169.03M-$55.11M$3.23B$257.73M7 Day Performance-1.86%0.68%-0.25%0.07%1 Month Performance-2.35%8.22%5.40%8.32%1 Year Performance-66.46%-2.64%26.35%13.78% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.3802 of 5 stars$7.85+2.2%$25.00+218.4%-66.0%$545.65M$25.72M-2.51240CGONCG Oncology2.5882 of 5 stars$26.25-2.4%$58.67+123.5%-31.9%$2.05B$1.14M-17.3861News CoveragePositive NewsAnalyst ForecastKNSAKiniksa Pharmaceuticals International3.5027 of 5 stars$27.95+0.3%$38.80+38.8%+30.0%$2.03B$423.24M-111.80220Upcoming EarningsBEAMBeam Therapeutics2.2702 of 5 stars$19.18-4.1%$48.75+154.2%-23.6%$2.01B$63.52M-4.16510IDYAIDEAYA Biosciences3.563 of 5 stars$21.16-4.3%$53.42+152.4%-48.2%$1.94B$7M-5.8980IRONDisc Medicine3.1994 of 5 stars$53.38-2.5%$96.70+81.2%+14.3%$1.90BN/A-13.6230Insider TradeBLTEBelite Bio1.9934 of 5 stars$58.63-1.4%$96.67+64.9%+29.2%$1.89BN/A-43.1110CNTACentessa Pharmaceuticals3.1596 of 5 stars$13.62-3.2%$27.89+104.8%+58.1%$1.88B$6.85M-7.52200HRMYHarmony Biosciences4.8363 of 5 stars$32.24+0.2%$53.63+66.3%+2.4%$1.85B$714.73M12.31200News CoveragePositive NewsADPTAdaptive Biotechnologies2.8401 of 5 stars$11.74-0.5%$10.57-10.0%+174.4%$1.79B$178.96M-12.23790SRPTSarepta Therapeutics4.7294 of 5 stars$17.32-5.0%$60.88+251.5%-88.1%$1.79B$1.90B-6.441,372 Related Companies and Tools Related Companies CG Oncology Competitors Kiniksa Pharmaceuticals International Competitors Beam Therapeutics Competitors IDEAYA Biosciences Competitors Disc Medicine Competitors Belite Bio Competitors Centessa Pharmaceuticals Competitors Harmony Biosciences Competitors Adaptive Biotechnologies Competitors Sarepta Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts